

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, June 15, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L5	L4 and (antigen or immunogen or vaccine)	52
<input type="checkbox"/>	L4	multilamellar same (mucosa\$ or nasal\$)	59
<input type="checkbox"/>	L3	L2 and (nasal or mucosa\$)	11
<input type="checkbox"/>	L2	L1 and (immunogen or antigen or vaccine)	25
<input type="checkbox"/>	L1	multilamellar same (liquid adj1 crystalline)	56

END OF SEARCH HISTORY

WEST Search History

DATE: Tuesday, June 15, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L7	L6 and 424/450.ccls.	0
<input type="checkbox"/>	L6	L5 and liposome	254
<input type="checkbox"/>	L5	(immunoglobulin) adj1 purif\$	524
<input type="checkbox"/>	L4	L3 and liposome	1364
<input type="checkbox"/>	L3	(immunoglobulin\$ or antibod\$) adj1 purif\$	4333
<input type="checkbox"/>	L2	L1 and liposome	3378
<input type="checkbox"/>	L1	(immunoglobulin\$ or antibod\$) adj3 purif\$	10698

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)☐ [Generate Collection](#) [Print](#)

L6: Entry 203 of 254

File: USPT

Dec 30, 1997

DOCUMENT-IDENTIFIER: US 5702946 A

TITLE: Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders

Drawing Description Text (65):

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

Drawing Description Text (99):

Suitable examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices include polyesters, hydrogels, polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers 22:547 (1983)), poly (2-hydroxyethyl-methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167 (1981) and Langer, Chem. Tech. 12:98 (1982)), ethylene vinyl acetate (Langer et al., supra) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release anti-IL-8 antibody compositions also include liposomally entrapped anti-IL-8 antibody. Liposomes containing anti-IL-8 antibody are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. U.S.A. 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. U.S.A. 77:4030 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mole percent cholesterol, the selected proportion being adjusted for the optimal anti-IL-8 antibody therapy.